Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
Dimple Butani,1 Nidhi Gupta,2 Gaurav Jyani,1 Pankaj Bahuguna,1 Rakesh Kapoor,3 Shankar Prinja1 1Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Department of Radiation Oncology, Government Medical College and...
Guardado en:
Autores principales: | Butani D, Gupta N, Jyani G, Bahuguna P, Kapoor R, Prinja S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9477f24e1a394e24902920eacd82c44f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Maura Harrigan, et al.
Publicado: (2021) -
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
por: Naiba Nabieva, et al.
Publicado: (2021) -
Association of Endocrine Therapy and Dementia in Women with Breast Cancer
por: Thompson MR, et al.
Publicado: (2021) -
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo QG, et al.
Publicado: (2016) -
Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Stefano Gonnelli, et al.
Publicado: (2008)